Literature DB >> 21669349

Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma.

Dingxin Wang1, Ron C Gaba, Brian Jin, Ahsun Riaz, Robert J Lewandowski, Robert K Ryu, Kent T Sato, Ann B Ragin, Laura M Kulik, Mary F Mulcahy, Riad Salem, Andrew C Larson, Reed A Omary.   

Abstract

RATIONALE AND
OBJECTIVES: To prospectively test the hypothesis that transcatheter intraarterial perfusion magnetic resonance imaging (TRIP-MRI) measured semiquantitative perfusion reductions during transcatheter arterial chemoembolization of hepatocellular carcinoma (HCC) are associated with tumor response.
MATERIALS AND METHODS: Twenty-eight patients (mean age 63 years; range 47-87 years) with 29 tumors underwent chemoembolization in a combined magnetic resonance interventional radiology suite. Intraprocedural tumor perfusion reductions during chemoembolization were monitored using TRIP-MRI. Pre- and postchemoembolization semiquantitative area under the time-signal enhancement curve (AUC) tumor perfusion was measured. Mean tumor perfusion pre- and postchemoembolization were compared using a paired t-test. Imaging follow-up was performed 1-3 months after chemoembolization. We studied the relationship between short-term tumor imaging response and intraprocedural perfusion reductions using univariate and multivariate analysis.
RESULTS: Intraprocedural AUC perfusion value decreased significantly after chemoembolization (342.1 vs. 158.6 arbitrary unit, P < .001). Twenty-six patients with 27 HCCs (n = 27) had follow-up imaging at mean 39 days postchemoembolization. Favorable response was present in 67% of these treated tumors according to necrosis criteria. Fifteen of 16 (94%) tumors with 25%-75% perfusion reductions showed necrosis treatment response compared to only 3 of 11 (27%) tumors with perfusion reductions outside the above range (P = .001). Multivariate logistic regression indicated that intraprocedural tumor perfusion reduction and Child-Pugh class were independent factors associated significantly with tumor response (P = .012 and .047, respectively).
CONCLUSION: TRIP-MRI can successfully measure semiquantitative changes in HCC perfusion during chemoembolization. Intraprocedural tumor perfusion reductions are associated with future tumor response.
Copyright © 2011 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21669349      PMCID: PMC3169325          DOI: 10.1016/j.acra.2011.02.016

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  34 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization.

Authors:  Johnathan C Chung; Neel K Naik; Robert J Lewandowski; Jie Deng; Mary F Mulcahy; Laura M Kulik; Kent T Sato; Robert K Ryu; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

3.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

4.  Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma.

Authors:  Dingxin Wang; Brian Jin; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Frank H Miller; Riad Salem; Debiao Li; Reed A Omary; Andrew C Larson
Journal:  J Magn Reson Imaging       Date:  2010-05       Impact factor: 4.813

5.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Chung-Mau Lo; Henry Ngan; Wai-Kuen Tso; Chi-Leung Liu; Chi-Ming Lam; Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

6.  Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

Authors:  Ahsun Riaz; Frank H Miller; Laura M Kulik; Paul Nikolaidis; Vahid Yaghmai; Robert J Lewandowski; Mary F Mulcahy; Robert K Ryu; Kent T Sato; Ramona Gupta; Ed Wang; Talia Baker; Michael Abecassis; Al B Benson; Albert A Nemcek; Reed Omary; Riad Salem
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

7.  Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.

Authors:  Ahsun Riaz; Khairuddin Memon; Frank H Miller; Paul Nikolaidis; Laura M Kulik; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Vanessa L Gates; Mary F Mulcahy; Talia Baker; Ed Wang; Ramona Gupta; Ritu Nayar; Al B Benson; Michael Abecassis; Reed Omary; Riad Salem
Journal:  J Hepatol       Date:  2010-10-23       Impact factor: 25.083

8.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

9.  Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model.

Authors:  A Jackson; H Haroon; X P Zhu; K L Li; N A Thacker; G Jayson
Journal:  NMR Biomed       Date:  2002-04       Impact factor: 4.044

10.  Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.

Authors:  Ahsun Riaz; Robert J Lewandowski; Laura Kulik; Robert K Ryu; Mary F Mulcahy; Talia Baker; Vanessa Gates; Ritu Nayar; Ed Wang; Frank H Miller; Kent T Sato; Reed A Omary; Michael Abecassis; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-05       Impact factor: 2.740

View more
  9 in total

1.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

2.  Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI.

Authors:  Bachir Taouli; R Scott Johnson; Cristina H Hajdu; Marcel T H Oei; Miriam Merad; Herman Yee; Henry Rusinek
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

3.  Transcatheter intra-arterial perfusion (TRIP)-MRI biomarkers help detect immediate response to irreversible electroporation of rabbit VX2 liver tumor.

Authors:  Matteo Figini; Kang Zhou; Liang Pan; Chong Sun; Bin Wang; Su Hu; Jia Yang; Junjie Shangguan; Aydin Eresen; Yury Velichko; Vahid Yaghmai; Zhuoli Zhang
Journal:  Magn Reson Med       Date:  2019-12-18       Impact factor: 4.668

4.  Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma.

Authors:  Dingxin Wang; Ron C Gaba; Brian Jin; Robert J Lewandowski; Ahsun Riaz; Khairuddin Memon; Robert K Ryu; Kent T Sato; Laura M Kulik; Mary F Mulcahy; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  Radiology       Date:  2014-03-28       Impact factor: 11.105

5.  Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.

Authors:  Kangan Li; Andrew C Gordon; Linfeng Zheng; Weiguo Li; Yang Guo; Jing Sun; Guixiang Zhang; Guohong Han; Andrew C Larson; Zhuoli Zhang
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

Review 6.  The status of transarterial chemoembolization treatment in the era of precision oncology.

Authors:  Valerie Fako; Xin Wei Wang
Journal:  Hepat Oncol       Date:  2017-09-26

Review 7.  MRI assessment of hepatocellular carcinoma after locoregional therapy.

Authors:  Rasha S Hussein; Wahid Tantawy; Yasser A Abbas
Journal:  Insights Imaging       Date:  2019-01-29

8.  Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.

Authors:  Nada Ezzeldin; Dalia El-Lebedy; Amira Darwish; Ahmed El Bastawisy; Shereen Hamdy Abd Elaziz; Mirhane Mohamed Hassan; Amal Saad-Hussein
Journal:  BMC Cancer       Date:  2018-05-03       Impact factor: 4.430

9.  The value of intra-procedural transcatheter intraarterial contrast-enhanced ultrasonography (IA-CEUS) in predicting the short-term efficacy of conventional transarterial chemoembolization (cTACE).

Authors:  Xiang Fei; Zhi-Jun Wang; Ye Li; Peng Han; Xiao-Hui Li; Bo Jiang
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.